<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>23(20)</volume><submitter>Ke J</submitter><pubmed_abstract>In recent years, cyclic peptides have attracted much attention due to their chemical and enzymatic stability, low toxicity, and easy modification. In general, the self-assembled nanostructures of cyclic peptides tend to form nanotubes in a cyclic stacking manner through hydrogen bonding. However, studies exploring other assembly strategies are scarce. In this context, we proposed a new assembly strategy based on cyclic peptides with covalent self-assembly. Here, cyclic peptide-(DPDPDP) was rationally designed and used as a building block to construct new assemblies. With cyclo-(DP)&lt;sub>3&lt;/sub> as the structural unit and 2,2'-diamino-N-methyldiethylamine as the linker, positively charged nanospheres ((CP)&lt;sub>6&lt;/sub>NS) based on cyclo-(DP)&lt;sub>3&lt;/sub> were successfully constructed by covalent self-assembly. We assessed their size and morphology by scanning electron microscopy (SEM), TEM, and DLS. (CP)&lt;sub>6&lt;/sub>NS were found to have a strong positive charge, so they could bind to siRNA through electrostatic interactions. Confocal microscopy analysis and cell viability assays showed that (CP)&lt;sub>6&lt;/sub>NS had high cellular internalization efficiency and low cytotoxicity. More importantly, real-time polymerase chain reaction (PCR) and flow cytometry analyses indicated that (CP)&lt;sub>6&lt;/sub>NS-siRNA complexes potently inhibited gene expression and promoted tumor cell apoptosis. These results suggest that (CP)&lt;sub>6&lt;/sub>NS may be a potential siRNA carrier for gene therapy.</pubmed_abstract><journal>International journal of molecular sciences</journal><pagination>12071</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9602810</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Design of Cyclic Peptide-Based Nanospheres and the Delivery of siRNA.</pubmed_title><pmcid>PMC9602810</pmcid><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Li J</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Ke J</pubmed_authors><pubmed_authors>Guan S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Design of Cyclic Peptide-Based Nanospheres and the Delivery of siRNA.</name><description>In recent years, cyclic peptides have attracted much attention due to their chemical and enzymatic stability, low toxicity, and easy modification. In general, the self-assembled nanostructures of cyclic peptides tend to form nanotubes in a cyclic stacking manner through hydrogen bonding. However, studies exploring other assembly strategies are scarce. In this context, we proposed a new assembly strategy based on cyclic peptides with covalent self-assembly. Here, cyclic peptide-(DPDPDP) was rationally designed and used as a building block to construct new assemblies. With cyclo-(DP)&lt;sub>3&lt;/sub> as the structural unit and 2,2'-diamino-N-methyldiethylamine as the linker, positively charged nanospheres ((CP)&lt;sub>6&lt;/sub>NS) based on cyclo-(DP)&lt;sub>3&lt;/sub> were successfully constructed by covalent self-assembly. We assessed their size and morphology by scanning electron microscopy (SEM), TEM, and DLS. (CP)&lt;sub>6&lt;/sub>NS were found to have a strong positive charge, so they could bind to siRNA through electrostatic interactions. Confocal microscopy analysis and cell viability assays showed that (CP)&lt;sub>6&lt;/sub>NS had high cellular internalization efficiency and low cytotoxicity. More importantly, real-time polymerase chain reaction (PCR) and flow cytometry analyses indicated that (CP)&lt;sub>6&lt;/sub>NS-siRNA complexes potently inhibited gene expression and promoted tumor cell apoptosis. These results suggest that (CP)&lt;sub>6&lt;/sub>NS may be a potential siRNA carrier for gene therapy.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Oct</publication><modification>2025-04-03T21:29:44.878Z</modification><creation>2025-04-03T21:29:44.878Z</creation></dates><accession>S-EPMC9602810</accession><cross_references><pubmed>36292932</pubmed><doi>10.3390/ijms232012071</doi></cross_references></HashMap>